The DOI matches its Crossref record; 118 of the 118 references it cites were found in a registry or an index.
SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity
Open accessAbstract
Seroprevalence surveys suggest that more than a third and possibly more than half of the global population has been infected with SARS-CoV-2 by early 2022. As large numbers of people continue to be infected, the efficacy and duration of natural immunity in terms of protection against SARS-CoV-2 reinfections and severe disease is of crucial significance for the future. This narrative review provides an overview on epidemiological studies addressing this issue. National surveys covering 2020-2021 documented that a previous SARS-CoV-2 infection is associated with a significantly reduced risk of reinfections with efficacy lasting for at least one year and only relatively moderate waning immunity. Importantly, natural immunity showed roughly similar effect sizes regarding protection against reinfection across different SARS-CoV-2 variants, with the exception of the Omicron variant for which data are just emerging before final conclusions can be drawn. Risk of hospitalizations and deaths was also reduced in SARS-CoV-2 reinfections versus primary infections. Observational studies indicate that natural immunity may offer equal or greater protection against SARS-CoV-2 infections compared to individuals receiving two doses of an mRNA vaccine, but data are not fully consistent. The combination of a previous SARS-CoV-2 infection and a respective vaccination, termed hybrid immunity, seems to confer the greatest protection against SARS-CoV-2 infections, but several knowledge gaps remain regarding this issue. Natural immunity should be considered for public health policy regarding SARS-CoV-2.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 3×
“Vaccination against SARS-CoV-2 proved to be highly efficacious in short-term randomized controlled trials (RCTs) and effective in real-life settings (Khandker et al., 2021; McIntyre et al., 2022; Polack et al., 2020; Sharif et al., 2021).”
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169
Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab
Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107934 · Cited by 1,086
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037
Waning Immunity after the BNT162b2 Vaccine in Israel
Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114228 · Cited by 1,034
Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00224-3 · Cited by 1,031
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers
Lumley, S. F., O’Donnell, D., Stoesser, N. E., Matthews, P. C., Howarth, A., Hatch, S. B., Marsden, B. D., Cox, S., James, T., Warren, F., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2034545 · Cited by 940
Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar
Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831
Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E. J. M., Simmons, R., Wellington, E., Cole, M. J., Saei, A., Oguti, B., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00675-9 · Cited by 638
REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Xiao, J., Hooper, A. T., Hamilton, J. D., Musser, B. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108163 · Cited by 632
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
Hansen, C. H., Michlmayr, D., Gubbels, S. M., Mølbak, K., & Ethelberg, S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00575-4 · Cited by 586
SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans
Turner, J. S., Kim, W., Kalaidina, E., Goss, C. W., Rauseo, A. M., Schmitz, A. J., Hansen, L., Haile, A., Klebert, M. K., Pusic, I., et al. (2021) · Nature · doi:10.1038/s41586-021-03647-4 · Cited by 529
Ma, Q., Liu, J., Liu, Q., Kang, L., Liu, R., Jing, W., Wu, Y., & Liu, M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.37257 · Cited by 472
Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2
Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L. S., Ash, N., Alroy-Preis, S., Huppert, A., & Milo, R. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2118946 · Cited by 467
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
Rössler, A., Riepler, L., Bante, D., von Laer, D., & Kimpel, J. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119236 · Cited by 466
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
Altarawneh, H. N., Chemaitelly, H., Hasan, M. R., Ayoub, H. H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Benslimane, F. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2200133 · Cited by 445
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
Dunkle, L. M., Kotloff, K. L., Gay, C. L., Áñez, G., Adelglass, J. M., Barrat Hernández, A. Q., Harper, W. L., Duncanson, D. M., McArthur, M. A., Florescu, D. F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116185 · Cited by 443
Immunological characteristics govern the transition of COVID-19 to endemicity
Lavine, J. S., Bjornstad, O. N., & Antia, R. (2021) · Science · doi:10.1126/science.abe6522 · Cited by 416
SARS-CoV-2 Variants and Vaccines
Krause, P. R., Fleming, T. R., Longini, I. M., Peto, R., Briand, S., Heymann, D. L., Beral, V., Snape, M. D., Rees, H., Ropero, A.-M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmsr2105280 · Cited by 366
Coronavirus disease 2019: The harms of exaggerated information and non‐evidence‐based measures
Ioannidis, J. P. A. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13222 · Cited by 364
Self-citationBuchan, S. A., Chung, H., Brown, K. A., Austin, P. C., Fell, D. B., Gubbay, J. B., Nasreen, S., Schwartz, K. L., Sundaram, M. E., Tadrous, M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.32760 · Cited by 356
Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada
Ulloa, A. C., Buchan, S. A., Daneman, N., & Brown, K. A. (2022) · JAMA · doi:10.1001/jama.2022.2274 · Cited by 316
BNT162b2 Vaccine Booster and Mortality Due to Covid-19
Arbel, R., Hammerman, A., Sergienko, R., Friger, M., Peretz, A., Netzer, D., & Yaron, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2115624 · Cited by 309
Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac262 · Cited by 283
Covid-19 Vaccine Effectiveness in New York State
Rosenberg, E. S., Dorabawila, V., Easton, D., Bauer, U. E., Kumar, J., Hoen, R., Hoefer, D., Wu, M., Lutterloh, E., Conroy, M. B., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116063 · Cited by 277
Association of SARS-CoV-2 Seropositive Antibody Test With Risk of Future Infection
Harvey, R. A., Rassen, J. A., Kabelac, C. A., Turenne, W., Leonard, S., Klesh, R., Meyer, W. A., Kaufman, H. W., Anderson, S., Cohen, O., et al. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.0366 · Cited by 272
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265
Household transmission of the SARS-CoV-2 Omicron variant in Denmark
Lyngse, F. P., Mortensen, L. H., Denwood, M. J., Christiansen, L. E., Møller, C. H., Skov, R. L., Spiess, K., Fomsgaard, A., Lassaunière, R., Rasmussen, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33328-3 · Cited by 255
Reduced risk of reinfection with SARS-CoV-2 after COVID-19 vaccination—Kentucky, May–June 2021
Cavanaugh, A. M., Spicer, K. B., Thoroughman, D., Glick, C., & Winter, K. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7032e1 · Cited by 240 · cited 5×
“…infection who remained unvaccinated had an odds ratio of 2.34 (95% CI: 1.58 to 3.47) for reinfections compared to previously infected individuals who received full vaccination by either two doses of an mRNA vaccine or a single dose of the Janssen (Johnson&Johnson) vaccine (Cavanaugh et al., 2021).”
InfluentialComparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis
Rotshild, V., Hirsh-Raccah, B., Miskin, I., Muszkat, M., & Matok, I. (2021) · Scientific Reports · doi:10.1038/s41598-021-02321-z · Cited by 233
Efficacy, Immunogenicity and Safety of COVID-19 Vaccines: A Systematic Review and Meta-Analysis
Sharif, N., Alzahrani, K. J., Ahmed, S. N., & Dey, S. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714170 · Cited by 230
Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity
Yahav, D., Yelin, D., Eckerle, I., Eberhardt, C. S., Wang, J., Cao, B., & Kaiser, L. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.11.028 · Cited by 229
Winter of Omicron—The Evolving COVID-19 Pandemic
del Rio, C., Omer, S. B., & Malani, P. N. (2022) · JAMA · doi:10.1001/jama.2021.24315 · Cited by 213
Protection against Covid-19 by BNT162b2 Booster across Age Groups
Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Alroy-Preis, S., Ash, N., Huppert, A., & Milo, R. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2115926 · Cited by 202
Jones, J. M., Stone, M., Sulaeman, H., Fink, R. V., Dave, H., Levy, M. E., Di Germanio, C., Green, V., Notari, E., Saa, P., et al. (2021) · JAMA · doi:10.1001/jama.2021.15161 · Cited by 201
(2021) · doi:10.1016/j.eclinm.2021.100861 · Cited by 201
SeroTracker: a global SARS-CoV-2 seroprevalence dashboard
Arora, R. K., Joseph, A., Van Wyk, J., Rocco, S., Atmaja, A., May, E., Yan, T., Bobrovitz, N., Chevrier, J., Cheng, M. P., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30631-9 · Cited by 200
Global perspective of COVID‐19 epidemiology for a full‐cycle pandemic
Ioannidis, J. P. A. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13423 · Cited by 195
Self-citationSeverity of SARS-CoV-2 Reinfections as Compared with Primary Infections
Abu-Raddad, L. J., Chemaitelly, H., & Bertollini, R. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2108120 · Cited by 189
Abu-Raddad, L. J., Chemaitelly, H., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Ayoub, H. H., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1846 · Cited by 180
Immune responses during COVID-19 infection
Melenotte, C., Silvin, A., Goubet, A., Lahmar, I., Dubuisson, A., Zumla, A. I., Raoult, D., Merad-Boudia, M., Gachot, B., Henon, C., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1807836 · Cited by 173
Immunity to SARS‐CoV‐2 induced by infection or vaccination
Castro Dopico, X., Ols, S., Loré, K., & Karlsson Hedestam, G. B. (2022) · Journal of Internal Medicine · doi:10.1111/joim.13372 · Cited by 166
Letizia, A. G., Ge, Y., Vangeti, S., Goforth, C. W., Weir, D. L., Kuzmina, N. A., Balinsky, C. A., Chen, H. W., Ewing, D. F., Schanoski, A. S., et al. (2021) · SSRN Electronic Journal · doi:10.1016/s2213-2600(21)00158-2 · Cited by 164
Protective immunity after recovery from SARS-CoV-2 infection
Kojima, N., & Klausner, J. D. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00676-9 · Cited by 163
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Tang, P., Hasan, M. R., Coyle, P., Al Kanaani, Z., et al. (2021) · JAMA · doi:10.1001/jama.2021.19623 · Cited by 162
SARS‐CoV‐2 re‐infection risk in Austria
Pilz, S., Chakeri, A., Ioannidis, J. P. A., Richter, L., Theiler‐Schwetz, V., Trummer, C., Krause, R. G. E., & Allerberger, F. J. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13520 · Cited by 158
Self-citationDoes infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Milne, G., Hames, T., Scotton, C. J., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00407-0 · Cited by 142
Sheehan, M. M., Reddy, A. J., & Rothberg, M. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab234 · Cited by 142
Singh, S., McNab, C., Olson, R. M., Bristol, N., Nolan, C., Bergstrøm, E., Bartos, M., Mabuchi, S., Panjabi, R., Karan, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01897-3 · Cited by 141
Vitale, J., Mumoli, N., Clerici, P., Paschale, M. D., Evangelista, I., Cei, M., & Mazzone, A. (2021) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.2959 · Cited by 140
COVID-19 Prevention and Control Measures in Workplace Settings: A Rapid Review and Meta-Analysis
Ingram, C., Downey, V., Roe, M., Chen, Y., Archibald, M., Kallas, K.-A., Kumar, J., Naughton, P., Uteh, C. O., Rojas-Chaves, A., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18157847 · Cited by 136
Ioannidis, J. P. A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13554 · Cited by 127
Self-citationDanza, P. Y., Koo, T. H., Haddix, M., Fisher, R. L., Traub, E., OYong, K., & Balter, S. E. (2022) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7105e1 · Cited by 119
Covid-19: Early studies give hope omicron is milder than other variants
Christie, B. (2021) · BMJ · doi:10.1136/bmj.n3144 · Cited by 113
Shenai, M. B., Rahme, R., & Noorchashm, H. (2021) · Cureus · doi:10.7759/cureus.19102 · Cited by 110
The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?
Boyton, R. J., & Altmann, D. M. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-021-00631-x · Cited by 107
Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection
Hanrath, A. T., Payne, B. A. I., & Duncan, C. J. A. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.12.023 · Cited by 106
Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines
Lewnard, J. A., Patel, M. M., Jewell, N. P., Verani, J. R., Kobayashi, M., Tenforde, M. W., Dean, N. E., Cowling, B. J., & Lopman, B. A. (2021) · Epidemiology · doi:10.1097/ede.0000000000001366 · Cited by 103
Vitamin D deficiency and the COVID-19 pandemic
ZEMB, P. A., Bergman, P., Camargo, C. A., Cavalier, E., Cormier, C., Courbebaisse, M., Hollis, B. W., Joulia, F., Minisola, S., Pilz, S., et al. (2020) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2020.05.006 · Cited by 101
Self-citationEggink, D., Andeweg, S. P., Vennema, H., van Maarseveen, N. M., Vermaas, K., Vlaemynck, B., Schepers, R., van Gageldonk-Lafeber, A. B., van den Hof, S., Reusken, C. B. E. M., et al. (2022) · Eurosurveillance · doi:10.2807/1560-7917.es.2022.27.4.2101196 · Cited by 97
A Systematic Review on COVID-19 Vaccine Strategies, Their Effectiveness, and Issues
Khandker, S. S., Godman, B., Jawad, M. I., Meghla, B. A., Tisha, T. A., Khondoker, M. U., Haq, M. A., Charan, J., Talukder, A. A., Azmuda, N., et al. (2021) · Vaccines · doi:10.3390/vaccines9121387 · Cited by 94
Efficacy of Natural Immunity against SARS-CoV-2 Reinfection with the Beta Variant
Chemaitelly, H. S., Bertollini, R., & Abu-Raddad, L. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2110300 · Cited by 94
Lusvarghi, S., Pollett, S., Neerukonda, S., Wang, W., Wang, R., Vassell, R., Epsi, N., Fries, A., Agan, B., Lindholm, D., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8543 · Cited by 93
COVID-19 vaccine strategies must focus on severe disease and global equity
McIntyre, P. B., Aggarwal, R., Jani, I. V., Jawad, J. S., Kochhar, S., MacDonald, N. E., Madhi, S. A., Mohsni, E., Mulholland, K., Neuzil, K. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02835-x · Cited by 91
Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection
Bates, T. A., McBride, S. K., Winders, B., Schoen, D., Trautmann, L., Curlin, M. E., & Tafesse, F. (2021) · JAMA · doi:10.1001/jama.2021.22898 · Cited by 91
A Systematic Review of the Protective Effect of Prior SARS-CoV-2 Infection on Repeat Infection
Kojima, N., Shrestha, N. K. M., & Klausner, J. D. (2021) · Evaluation & the Health Professions · doi:10.1177/01632787211047932 · Cited by 90
Bozio, C. H., Grannis, S. J., Naleway, A. L., Ong, T. C., Butterfield, K. A., DeSilva, M. B., Natarajan, K., Yang, D., Rao, S., Klein, N. P., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7044e1 · Cited by 90
Correlates of protection from SARS-CoV-2 infection
Krammer, F. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00782-0 · Cited by 89
Global public health security and justice for vaccines and therapeutics in the COVID-19 pandemic
Hotez, P. J., Batista, C., Amor, Y. B., Ergönül, Ö., Figueroa, J. P., Gilbert, S. C., Gürsel, M., Hassanain, M. M., Kang, G., Kaslow, D. C., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101053 · Cited by 89
Quantifying the risk of SARS‐CoV‐2 reinfection over time
O Murchu, E., Byrne, P., Carty, P. G., De Gascun, C., Keogan, M., O’Neill, M., Harrington, P., & Ryan, M. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2260 · Cited by 84
Abu-Raddad, L. J., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Hasan, M. R., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Kanaani, Z. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28199-7 · Cited by 81
Qureshi, A. I., Baskett, W. I., Huang, W., Lobanova, I., Naqvi, S. H., & Shyu, C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab345 · Cited by 80
Lumley, S., Rodger, G., Constantinides, B., Sanderson, N. D., Chau, K., Street, T. L., O’Donnell, D., Howarth, A., Hatch, S. B., Marsden, B. D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab608 · Cited by 77
Lau, E. H. Y., Hui, D. S. C., Tsang, O. T., Chan, W. H., Kwan, M. Y. W., Chiu, S. S. S., Cheng, S. M. S., Ko, R. L., Li, J. K., Chaothai, S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101174 · Cited by 72
Leidi, A., Koegler, F., Dumont, R., Dubos, R., Zaballa, M.-E., Piumatti, G., Coen, M., Berner, A., Farhoumand, P. D., Vetter, P., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab495 · Cited by 66
Havervall, S., Ng, H., Falk, A. J., Greilert‐Norin, N., Månberg, A., Marking, U. W., Laurén, I., Gabrielsson, L., Salomonsson, A., Aguilera, K., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13387 · Cited by 66
Goldberg, Y., Mandel, M., Woodbridge, Y., Fluss, R., Novikov, I., Yaari, R., Ziv, A., Freedman, L. S., & Huppert, A. (2022) · American Journal of Epidemiology · doi:10.1093/aje/kwac060 · Cited by 65
Jeffery-Smith, A., Rowland, T. A. J., Patel, M., Whitaker, H., Iyanger, N., Williams, S. V., Giddings, R., Thompson, L., Zavala, M., Aiano, F., et al. (2021) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(21)00253-1 · Cited by 63
Infection fatality rate of COVID-19 in community-dwelling elderly populations
Axfors, C., & Ioannidis, J. P. A. (2022) · European Journal of Epidemiology · doi:10.1007/s10654-022-00853-w · Cited by 63
Self-citationKim, P., Gordon, S. M., Sheehan, M. M., & Rothberg, M. B. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab999 · Cited by 62
Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients
Slezak, J. M., Bruxvoort, K. J., Fischer, H. J., Broder, B. I., Ackerson, B. K., & Tartof, S. Y. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.07.030 · Cited by 60
Garrido, C., Hurst, J. H., Lorang, C. G., Aquino, J. N., Rodriguez, J., Pfeiffer, T. S., Singh, T., Semmes, E. C., Lugo, D. J., Rotta, A. T., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150909 · Cited by 56
Abu-Raddad, L. J., Chemaitelly, H., Ayoub, H. H., Coyle, P., Malek, J. A., Ahmed, A. A., Mohamoud, Y. A., Younuskunju, S., Tang, P., Al Kanaani, Z., et al. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003879 · Cited by 54
Breathnach, A. S., Riley, P. A., Cotter, M., Houston, A., Habibi, M. S., & Planche, T. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.01.005 · Cited by 51
COVID‐19 vaccination in children and university students
Ioannidis, J. P. A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13678 · Cited by 49
Self-citationLong, H., Zhao, J., Zeng, H., Lu, Q., Fang, L., Wang, Q., Wu, Q., & Liu, W. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-07002-w · Cited by 48
Benefit of COVID-19 Vaccination Accounting for Potential Risk Compensation
Ioannidis, J. P. A. (2021) · npj Vaccines · doi:10.1038/s41541-021-00362-z · Cited by 44
Self-citationAyoub, H. H., Tomy, M., Chemaitelly, H. S., Altarawneh, H. N., Coyle, P. V., Tang, P., Hasan, M. R., Kanaani, Z. A., Al‐Kuwari, E., Butt, A. A., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad239 · Cited by 41
Jahan, N., Brahma, A., Kumar, M. S., Bagepally, B. S., Ponnaiah, M., Bhatnagar, T., & Murhekar, M. V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.12.353 · Cited by 38
Predictors of severe symptomatic laboratory-confirmed SARS-CoV-2 reinfection
Murillo‐Zamora, E., Hernández-Suárez, C., Lugo-Radillo, A., Aguilar-Sollano, F., & Mendoza‐Cano, O. (2021) · Public Health · doi:10.1016/j.puhe.2021.01.021 · Cited by 37
Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection
Dehgani‐Mobaraki, P., Zaidi, A. K., Yadav, N., Floridi, A., & Floridi, E. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108814 · Cited by 37
Spicer, K. B., Glick, C., Cavanaugh, A. M., & Thoroughman, D. A. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.10.010 · Cited by 37
Rosati, M., Terpos, E., Ntanasis‐Stathopoulos, I., Agarwal, M., Bear, J., Burns, R. T., Hu, X., Korompoki, E., Donohue, D. E., Venzon, D. J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793953 · Cited by 36
Rennert, L., & McMahan, C. S. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab454 · Cited by 34
Prior COVID-19 protects against reinfection, even in the absence of detectable antibodies
Breathnach, A. S., Duncan, C. J. A., Bouzidi, K. E., Hanrath, A. T., Payne, B. A. I., Randell, P. A., Habibi, M. S., Riley, P. A., Planche, T., Busby, J., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.05.024 · Cited by 33
Chen, S., Flegg, J. A., White, L. J., & Aguas, R. J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009436 · Cited by 29
Calling for benefit–risk evaluations of COVID-19 control measures
Kampf, G., & Kulldorff, M. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00193-8 · Cited by 26
Peghin, M., Bouza, E., Fabris, M., Martino, M. D., Palese, A., Bontempo, G., Graziano, E., Gerussi, V., Bressan, V., Sartor, A., et al. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04335-x · Cited by 26
Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity
Fakhroo, A. D., Al-Khatib, H. A., Thani, A. A. A., & Yassine, H. M. (2021) · Vaccines · doi:10.3390/vaccines9101168 · Cited by 26
ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections
Satwik, R., Satwik, A., Katoch, S., & Saluja, S. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.08.005 · Cited by 25
Flacco, M. E., Martellucci, C. A., Soldato, G., Carota, R., Fazii, P., Caponetti, A., & Manzoli, L. (2021) · Journal of Public Health · doi:10.1093/pubmed/fdab346 · Cited by 24
Cheng, Q., Chen, J., Jia, Q., Fang, Z., & Zhao, G. (2021) · Aging · doi:10.18632/aging.203522 · Cited by 23
Schuler, C. F., IV, Gherasim, C., O’Shea, K. J., Manthei, D. M., Chen, J., Zettel, C., Troost, J. P., Kennedy, A. A., Tai, A. W., Giacherio, D. A., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00087-21 · Cited by 22
Long-Lasting Immunity Against SARS-CoV-2: Dream or Reality?
Gussarow, D., Bonifacius, A., Cossmann, A., Stankov, M. V., Mausberg, P., Tischer‐Zimmermann, S., Gödecke, N., Kalinke, U., Behrens, G. M. N., Blasczyk, R., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.770381 · Cited by 20
Petráš, M. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.08.042 · Cited by 19
Muzio, L. L., Ambosino, M., Muzio, E. L., & Quadri, M. F. A. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182011001 · Cited by 17
Iversen, K. K., Kristensen, J. H., Hasselbalch, R. B., Pries‐Heje, M. M., Nielsen, P. B., Knudsen, A. D., Fogh, K., Norsk, J. B., Andersen, O., Fischer, T. K., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.005 · Cited by 16
Lee, J. T., Hesse, E. M., Paulin, H. N., Datta, D., Katz, L. S., Talwar, A., Chang, G., Galang, R. R., Harcourt, J. L., Tamin, A., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab148 · Cited by 15
Ringlander, J., Olausson, J., Nyström, K., Härnqvist, T., Jakobsson, H. E., & Lindh, M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1957143 · Cited by 14
Recurrent SARS-CoV-2 infections and their potential risk to public health – a systematic review
Abrokwa, S. K., Müller, S. A., Méndez-Brito, A., Hanefeld, J., & Bcheraoui, C. E. (2021) · PLoS ONE · doi:10.1371/journal.pone.0261221 · Cited by 11
Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
Gentile, I., Maraolo, A. E., Buonomo, A. R., Nobile, M., Piscitelli, P., Miani, A., & Moriello, N. S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111159 · Cited by 10
Chellamuthu, P., Angel, A. N., MacMullan, M. A., Denny, N., Mades, A., Santacruz, M., Lopez, R., Bagos, C., Casian, J. G., Trettner, K., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.777858 · Cited by 10
Letter to the Editor Re: Global perspective of COVID‐19 epidemiology for a full‐cycle pandemic
Pilz, S. (2020) · European Journal of Clinical Investigation · doi:10.1111/eci.13447 · Cited by 1
Self-citation
Cited by
SARS-CoV-2 Omicron variant: recent progress and future perspectives
Fan, Y., Li, X., Zhang, L., Wan, S., Zhang, L., & Zhou, F. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00997-x · Cited by 589
Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections
Altarawneh, H. N., Chemaitelly, H., Ayoub, H. H., Tang, P., Hasan, M. R., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Coyle, P., Al-Kanaani, Z., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203965 · Cited by 551
Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis
Stein, C., Nassereldine, H., Sorensen, R. J. D., Amlag, J. O., Bisignano, C., Byrne, S., Castro, E., Coberly, K., Collins, J. K., Dalos, J., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(22)02465-5 · Cited by 412
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
(2022) · doi:10.1038/s41467-022-32363-4 · Cited by 84
Protection of Omicron sub-lineage infection against reinfection with another Omicron sub-lineage
Chemaitelly, H., Ayoub, H. H., Coyle, P., Tang, P., Yassine, H. M., Al-Khatib, H. A., Smatti, M. K., Hasan, M. R., Al-Kanaani, Z., Al-Kuwari, E., et al. (2022) · doi:10.1101/2022.02.24.22271440 · Cited by 84
Metadata
- Authors
- Pilz, S., Theiler-Schwetz, V., Trummer, C., Krause, R., & Ioannidis, J. P. A.
- Venue
- Environmental Research
- Publisher
- Elsevier BV
- Published
- 2022-06
- Volume
- 209
- Pages
- 112911
- ISSN
- 0013-9351 (ISSN-L)
- OpenAlex
- W4225574157
- Cited by
- 264
- References
- 118
- FWCI
- 28.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.